Epistaxis associated with elevation of INR in a patient switched to generic warfarin - Another view

Pharmacotherapy

Volumn 20, Issue 7 I, 2000, Pages 866-871

  Meibohm, Bernd ^a   Zhang, Wenhui ^a   Beierle, Ingrid ^a   Meyer, Marvin C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; WARFARIN;

ANTICOAGULANT THERAPY; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL STANDARD UNIT; REVIEW; TABLET PROPERTY;

EID: 0033920460     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.9.866.35190     Document Type: Review

References (16)

1. Haines ST. Reflections on generic warfarin. Am J Health-Syst Pharm 1998;55:72-33.
2. Benson SR, Vance-Bryan K. In favor of Coumadin over generic warfarin. Am J Health-Syst Pharm 1998;55:727-9.
3. Wittkowsky AK. Generic warfarin: implications for patient care. Pharmacotherapy 1997;17:640-3.
4. Meyer MC, Chan K, Bolton S. Generic warfarin: implications for patient care - another view. Pharmacotherapy 1998;18:884-6.
5. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations, 19th ed. Rockville, MD; 1999.
6. Wagner JL, Dent LA. Epistaxis associated with elevation of INR in a patient switched to generic warfarin. Pharmacotherapy 2000;20(2):240-3.
7. GiaQuinto NJ. Are all warfarin preparations alike? A comprehensive overview of current data, emerging, opinions, and perspectives. J Thromb Thrombolysis 2000;9:139-44.
8. Vadher B, Patterson DL, Leaning M. Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. Br J Clin Pharmacol 1999;48:63-70.
9. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the close-effect relationship. Clin Pharmacokinet 1986;11:483-504.
10. United States Pharmacopoeia. Content uniformity 2001-2002. Rockville, MD: USP 24 Convention, 2000.
11. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acctaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-62.
12. Neutel JM, Smith DHG. A randomized, crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep 1998;19:49-59.
13. Handler J, Nguyen TT, Rush S, Pham NT. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prev Cardiol 1998;4:13-20.
14. Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization. Am J Health-Syst Pharm 2000; 57:452-5.
15. Plowman BK, Morreale AP, Mehdigholi E. A comparative analysis of Coumadin and generic warfarin [abstr]. Pharmacotherapy 2000; 20:346.
16. Noviasky JA. Evidence-based pharmacy versus opinion on generic product selection of warfarin. Am J Health-Syst Pharm 1999; 56:2246-7.